It was a relatively small study, and patients were only followed for six months, but these late-breaking data out of ESC Congress 2026 give care teams a lot to consider.
Many patients who need TAVR also present with coronary artery disease. According to new data presented at ESC Congress 2026, performing TAVR first is noninferior to performing PCI first.
New data presented at ESC Congress 2026 represent a huge breakthrough for patients with nonobstructive HCM. "For the first time, we have shown clinically meaningful improvements in symptoms and exercise capacity with a treatment that targets the cause of the disease," one researcher explained.
Imager II Angiographic Catheters. Image courtesy of Boston Scientific.
The issue, brought on by a manufacturing defect, has been linked to two serious injuries. The FDA shared an early alert about the situation as it continues its investigation.
The new guidelines, published in European Heart Journal and presented at ESC Congress 2026, show just how much heart failure care has evolved in recent years.
More than 95% of congenital heart patients now survive into adulthood, leaving clinicians with much more ground to cover than ever before. Providing high-quality care for these patients requires specialty care as well as collaborations with general cardiologists.
The popular diabetes drug, sold by Eli Lilly and Company under the brand name Mounjaro, has been at the center of many cardiology trials over the years. It is the first dual GIP and GLP-1 hormone receptor agonist approved by the FDA for this indication.
